Deal Announcement

DC Advisory advised Graphite Capital on its acquisiton of Random42 from Vespa Capital and shareholders

17 Jul 2017

Random42 is one of the largest global medical animation producers. Animation is increasingly seen as a critical component of the marketing programme surrounding new drug development as well as having wider corporate uses

DC Advisory (DC) were engaged by Graphite Capital (Graphite) in May 2017 to provide M&A advice in relation to the acquisition of Random42

DC assisted in valuation guidance, assessment of market dynamics and potential exit options for Random42

On 21 July 2017, Graphite announced the acquisition of Random42 for an undisclosed consideration

With Graphite’s support, Random42 will focus on increasing its market share, building on its expertise and strong track record.  It will look to increase its geographic coverage further by expanding in Europe and the Far East while continuing to grow its core North American sales. The company will also explore opportunities in new markets such as educational materials, corporate promotions, animal health, over-the-counter drugs and medical devices

Deal Team

David Sanders

Executive Director
United Kingdom

Humphrey Baker, Partner at Graphite Capital, commented:
“We greatly valued DC Advisory’s strategic insight, process leadership and strong M&A execution capabilities which were critical to completing the transaction within a short timeframe.”

David Sanders, Executive Director at DC Advisory, commented:
“We are delighted to have worked with Graphite on its investment in Random42. Ben and his colleagues have built the business into a leader in a high-growth market, and Graphite will be an ideal partner to take Random42 to the next level.”